stock
JNJ · JOHNSON & JOHNSON
What JOHNSON & JOHNSON reports to the SEC, read from its filings.
Open in the appPrice
The live JNJ price and today's change.
Sign in to see thisChart
Thirty days of daily bars, with signal levels drawn on them.
Sign in to see thisSignals
The latest signal group Nakagai's scanner recorded on JNJ.
Sign in to see thisOptions positioning
Gamma exposure levels from the options market.
Sign in to see thisTechnicals
Trend, momentum and volatility gauges per timeframe.
Sign in to see thisWhat it is
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Filer (SEC EDGAR)
- EDGAR filing index
- Shares outstanding
- 2,409,898,597 as of 2026-07-17 (XBRL frame CY2026Q2I)
Key stats
Valuation
- P/E
- Locked
- P/S
- Locked
- P/B
- Locked
- Enterprise value
- Locked
- EV/EBIT
- Locked
- FCF yield
- Locked
Margins
- Gross
- 67.9%
- Operating
- —
- Net
- 21.5%
Returns
- ROE
- 24.8%
- ROA
- 10.5%
Health
- Current ratio
- 1.1x
- Debt/equity
- 0.4x
Deep value
- NCAV
- -$56.32B
- NCAV per share
- -$23.37
- Price/NCAV
- Locked
- NNWC
- -$73.81B
- NNWC per share
- -$30.63
- Price/NNWC
- Locked
Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-28; balance sheet at 2026-06-28.
Sign in to see thisDebt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.
Results
| Period end | Revenue | Gross profit | Operating income | Net income | Filing |
|---|---|---|---|---|---|
| 2026-06-28 | $25.31B | $17.26B | — | $5.53B | 10-Q filed 2026-07-23 |
| 2026-03-29 | $24.06B | $15.96B | — | $5.24B | 10-Q filed 2026-04-22 |
| 2025-12-28 | $24.56B | $16.60B | — | $5.12B | 10-K filed 2026-02-11 Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. |
| 2025-09-28 | $23.99B | $16.69B | — | $5.15B | 10-Q filed 2025-10-22 |
| 2025-06-29 | $23.74B | $16.11B | — | $5.54B | 10-Q filed 2026-07-23 |
| 2025-03-30 | $21.89B | $14.54B | — | $11.00B | 10-Q filed 2026-04-22 |
| 2024-12-29 | $22.52B | $15.39B | — | $3.43B | 10-K filed 2026-02-11 Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. |
| 2024-09-29 | $22.47B | $15.51B | — | $2.69B | 10-Q filed 2025-10-22 |
- Assets
- $201.06B
- Equity
- $84.97B
Balance as of 2026-06-28.
Ten years
| Fiscal year end | Revenue | Operating income | Net income | Free cash flow |
|---|---|---|---|---|
| 2025-12-28 | $94.19B | — | $26.80B | $19.70B |
| 2024-12-29 | $88.82B | — | $14.07B | $19.84B |
| 2023-12-31 | $85.16B | — | $35.15B | $18.25B |
| 2023-01-01 | $79.99B | — | $17.94B | $17.18B |
| 2022-01-02 | $78.74B | — | $20.88B | $19.76B |
| 2021-01-03 | $82.58B | — | $14.71B | $20.19B |
| 2019-12-29 | $82.06B | — | $15.12B | $19.92B |
| 2018-12-30 | $81.58B | — | $15.30B | $18.53B |
| 2017-12-31 | $76.45B | — | $1.30B | $17.78B |
| 2017-01-01 | $71.89B | — | $16.54B | $15.54B |
Company filings
since Wed Feb 11
events
Executive or director change
Executive or director changeAug 48-KRegulation FD disclosure
Regulation FD disclosureJul 298-KRegulation FD disclosure
Regulation FD disclosureJul 278-KResults
ResultsJul 158-KShareholder vote results
Shareholder vote resultsApr 278-KResults, Other event
ResultsOther eventApr 148-K
5% owners ()
Vanguard Capital Management
Passive stake
The Vanguard Group
Stake update
The Vanguard Group
Stake update
Insiders, politicians and funds
Insider trades, last 90 days
Schmid Timothy
EVP, WW Chair, MedTech
Sale$9,230,440Sep 4, 9:08 AM ET
Taubert Jennifer L
EVP, WWC. Innovative Medicine
Sale$3,950,400Aug 18, 6:31 PM ET
Duato Joaquin
CEO and Chairman of the Board, Director
Sale$32,199,927Aug 14, 4:35 PM ET
Duato Joaquin
CEO and Chairman of the Board, Director
Sale$12,515,010Aug 7, 5:50 PM ET
Forminard Elizabeth
EVP, Chief Legal Officer
Sale$4,090,960Aug 7, 5:44 PM ET
Politician trades, last 90 days
Thomas H. Kean
House · NJ07
SalePartial$1,001 to $15,000Sat Sep 12
John Boozman
Senate
SalePartial$1,001 to $15,000Fri Sep 11
Richard Dean Dr McCormick
House · GA06
Sale$1,001 to $15,000Fri Aug 14
Thomas H Tuberville
Senate
Sale$15,001 to $50,000Wed Aug 5
Thomas H Tuberville
Senate
Sale$15,001 to $50,000Wed Aug 5
Funds
- Yacktman Asset Management
Period Tue 30 Jun 2026
4.0%Added - Tweedy Browne
Period Tue 30 Jun 2026
3.9%Trimmed - Markel Group
Period Tue 30 Jun 2026
1.2%Same - Bridgewater Associates
Period Tue 30 Jun 2026
0.7%Trimmed - Point72
Puts · Period Tue 30 Jun 2026
0.5%Added
News
Stories that named JNJ, and the market events around them.
Sign in to see thisBoard
Recent signals
Signals open up here once a member has posted about JNJ.
Signals are informational.
Posts · 0
No posts yet.
nakagai
Signals on JNJ come from a rule, not a model.
Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.
Members post on the JNJ board